1237745-88-8 Usage
Quinoline ring
A tricyclic aromatic compound consisting of a benzene ring fused to a pyridine ring.
Thiazole ring
A five-membered heterocyclic ring containing one sulfur atom and one nitrogen atom.
Cyclopropyl group
A three-carbon ring with a single bond between two of the carbon atoms.
Protein kinases
Enzymes that play a crucial role in cell signaling and regulation by transferring phosphate groups from ATP to proteins.
Inhibition
The compound may interfere with the activity of protein kinases, potentially leading to therapeutic effects.
Anti-cancer properties
The compound has shown potential in inhibiting the growth and spread of cancer cells.
Anti-inflammatory properties
The compound may help reduce inflammation by modulating the activity of protein kinases involved in inflammatory responses.
Potential therapeutic applications
Due to its anti-cancer and anti-inflammatory properties, the compound may be further developed as a new drug for the treatment of cancer and inflammatory diseases.
Interesting subject for research
The compound's unique chemical structure and its potential therapeutic effects make it a valuable subject for further investigation in medicinal chemistry and pharmacology.
Check Digit Verification of cas no
The CAS Registry Mumber 1237745-88-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,7,7,4 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1237745-88:
(9*1)+(8*2)+(7*3)+(6*7)+(5*7)+(4*4)+(3*5)+(2*8)+(1*8)=178
178 % 10 = 8
So 1237745-88-8 is a valid CAS Registry Number.
1237745-88-8Relevant articles and documents
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups
Li, Xianfeng,Liu, Yang,Zhang, Yong-Kang,Plattner, Jacob J.,Baker, Stephen J.,Bu, Wei,Liu, Liang,Zhou, Yasheen,Ding, Charles Z.,Zhang, Suoming,Kazmierski, Wieslaw M.,Hamatake, Robert,Duan, Maosheng,Wright, Lois L.,Smith, Gary K.,Jarvest, Richard L.,Ji, Jing-Jing,Cooper, Joel P.,Tallant, Matthew D.,Crosby, Renae M.,Creech, Katrina,Wang, Amy
, p. 7351 - 7356 (2013/02/21)
We have synthesized and evaluated a series of novel HCV NS3 protease inhibitors with various P4 capping groups, which include urea, carbamate, methoxy-carboxamide, cyclic carbamate and amide, pyruvic amide, oxamate, oxalamide and cyanoguanidine. Most of these compounds are remarkably potent, exhibiting single-digit to sub-nanomolar activity in the enzyme assay and cell-based replicon assay. Selected compounds were also evaluated in the protease-inhibitor-resistant mutant transient replicon assay, and they were found to show quite different potency profiles against a panel of HCV protease-inhibitor-resistant mutants.
